bcrx buy initiated $21 target

H.C. Wainwright begins coverage of BioCryst Pharmaceuticals (BCRX) with a Buy rating and $21 price target.Friday's close was $11.46.Consensus revenue estimates for 2014 and 2015 are $11.9M and $71M, respectively.49 mutual funds have positions, down from 89 a year earlier.

------

Hey Russ, can you call H.C. Wainwright and put on the tea and scones so they can initiate a buy rating on BOTA? $18 will do.

BCRX $21 - Heavens knows what is in the water over there, but if BOTA follows suit, I want some of that over here pronto for some of my other stocks too.